First, a Quick Scorecard
Before diving into mechanisms and trial data, here’s the landscape in one paragraph: Ozempic (semaglutide, up to 1 mg weekly) is FDA-approved for type 2 diabetes. For weight loss specifically, it’s used off-label and produces roughly 6–8% body weight reduction in clinical trials involving diabetic populations. Wegovy is the same molecule — semaglutide — but titrated to a higher 2.4 mg dose and approved explicitly for chronic weight management. It delivers roughly 15% average weight loss. Mounjaro (tirzepatide) is a different molecule entirely — a dual GLP-1/GIP receptor agonist — and produces the largest reductions: roughly 15–21% depending on dose, with selected trial populations losing over 20% of starting body weight at the highest 15 mg dose.
If that’s all you needed, there it is. But the real picture is more textured, and the differences matter.
| Medication (molecule) | FDA-approved for | Weight loss reported in the trials cited above | Notes from this article |
|---|---|---|---|
| Ozempic (semaglutide) | Type 2 diabetes — weight loss use is off-label | Roughly 6–8% in trials of people with diabetes | Up to 1 mg weekly (2 mg in select markets); ~$1,028/month list price; not included in the Medicare GLP-1 Bridge pilot |
| Wegovy (semaglutide) | Chronic weight management; also approved for adolescents 12+ with obesity | STEP 1: 14.9% over 68 weeks (2.4% on placebo); ~15% average | 2.4 mg weekly; ~$1,349/month list price; covered by the Medicare Bridge pilot at a $50/month copay for BMI 35+ |
| Mounjaro (tirzepatide) | Type 2 diabetes — weight loss use is off-label | SURMOUNT-1 (15 mg): 20.9% over 72 weeks; SURMOUNT-5: 20.2% | Dual GLP-1/GIP agonist; up to 15 mg; ~$1,069–1,079/month list price; not included in the Medicare Bridge pilot |
| Zepbound (tirzepatide) | Chronic weight management | SURMOUNT-5 tirzepatide arm: 20.2% (same molecule as Mounjaro) | ~$1,086/month list price; KwikPens covered by the Medicare Bridge pilot |
| Saxenda (liraglutide) | Chronic weight management | Typically 5–10% | Older GLP-1 option named in this article’s FAQ; weekly dosing interval not stated here |
What These Drugs Actually Are
All three medications belong to a class called incretin mimetics — drugs that imitate hormones your gut naturally produces after eating. But the specific receptors they target differ, and that difference is where the weight-loss gap originates.
Ozempic and Wegovy both contain semaglutide, a GLP-1 (glucagon-like peptide-1) receptor agonist. GLP-1 is a hormone your small intestine releases when food arrives. It tells your pancreas to release insulin, tells your liver to stop making glucose, slows down how fast your stomach empties, and — critically — signals your brain that you’re full. Semaglutide mimics all of this, just at pharmacological levels that far exceed what your body produces naturally. The difference between Ozempic and Wegovy is purely dosing: Ozempic maxes out at 1 mg weekly (sometimes 2 mg in select markets), while Wegovy goes to 2.4 mg. Same drug, different label, different ceiling.
Mounjaro (tirzepatide) goes further. It targets two incretin receptors: GLP-1 and GIP (glucose-dependent insulinotropic polypeptide). GIP enhances insulin secretion in its own right and appears to amplify the weight-loss effect of GLP-1 activation when the two are combined. This dual mechanism is widely considered the reason tirzepatide consistently outperforms semaglutide in head-to-head comparisons — it’s not just a stronger version of the same thing. It’s hitting a second pathway the single-agonist drugs don’t touch.
Understanding how these drugs affect blood sugar — and why that matters for weight — goes deeper than most people realize. For a full breakdown of the connection between blood sugar swings, cravings, and stubborn weight, read our guide to blood sugar dysregulation, fatigue, and cravings.
The Numbers That Matter: Trial Results Head-to-Head
Clinical trials aren’t real life — they’re tightly controlled, patients are selected, adherence is monitored. But they’re the best comparison tool we have, and the data is unambiguous.
In the STEP 1 trial, adults without diabetes taking Wegovy 2.4 mg lost an average of 14.9% of their body weight over 68 weeks, compared to 2.4% on placebo. About a third of participants lost 20% or more.
In SURMOUNT-1, adults without diabetes taking tirzepatide (Mounjaro/Zepbound) at the highest 15 mg dose lost an average of 20.9% of body weight over 72 weeks. At the 10 mg dose, 50% of participants hit at least 20% weight loss. At 15 mg, nearly 57% did.
The real showdown came in May 2025 with SURMOUNT-5, the first randomized head-to-head trial pitting the two molecules directly against each other at maximum tolerated doses over 72 weeks. The results, published in the New England Journal of Medicine:
- Tirzepatide: 20.2% average weight loss (22.8 kg / 50.3 lbs)
- Semaglutide: 13.7% average weight loss (15.0 kg / 33.1 lbs)
- 64.6% of tirzepatide users hit at least 15% weight loss vs. 40.1% on semaglutide
- 32% of tirzepatide users lost 25% or more of their body weight vs. 16% on semaglutide
A large real-world study published in JAMA Internal Medicine in 2024 tracking over 18,000 matched patients found similar patterns outside trial conditions. At 12 months, tirzepatide patients had lost roughly 15% of body weight versus roughly 8% on semaglutide — a near-doubling of effect. The gap widened with duration.
One nuance worth noting: Novo Nordisk has been testing a higher 7.2 mg dose of Wegovy, and early data suggests it narrows the gap with tirzepatide. But as of mid-2026, that dose isn’t yet FDA-approved for weight management. For now, tirzepatide has the clear efficacy edge.
The Side Effect Profile: What to Actually Expect
The side effect conversation around these drugs tends toward extremes — either “it’s nothing, everyone tolerates it fine” or “it’ll wreck your digestive system.” The truth sits in between, and it’s remarkably consistent across all three medications.
The most common side effects are gastrointestinal. Nausea hits roughly 20–44% of semaglutide users and 17–25% of tirzepatide users, varying by dose and how quickly patients titrate up. Diarrhea, constipation, vomiting, and abdominal discomfort round out the list. These are almost always worst during the first four to eight weeks as the body adapts, then diminish. Slow, stepwise dose escalation — the standard prescribing approach — reduces severity substantially.
In the SURMOUNT-5 head-to-head, gastrointestinal side effects leading to treatment discontinuation were slightly more common on semaglutide than tirzepatide, though both were generally well tolerated. Constipation appears somewhat more common on tirzepatide, possibly because the GIP receptor adds a separate effect on gut motility.
For a deeper look at the safety landscape — including the long-term risks, the data on pancreatitis and gallbladder complications, and what monitoring looks like — see our comprehensive GLP-1 safety guide.
All three drugs carry an FDA boxed warning for thyroid C-cell tumors, based on rodent studies. The relevance to humans remains unconfirmed — large-scale reviews published through 2025 have not found an association with common thyroid cancers — but the warning carries real clinical weight. The drugs are contraindicated in anyone with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). This warning applies across the entire GLP-1 class, not just to one brand.
Who Should Take These — and Who Absolutely Shouldn’t
Good Candidates
FDA labeling draws a clear line: these drugs are indicated for adults with a BMI of 30 or higher (obesity), or a BMI of 27 or higher (overweight) with at least one weight-related comorbidity — hypertension, type 2 diabetes, dyslipidemia, or obstructive sleep apnea. Wegovy is also approved for adolescents aged 12 and up with obesity.
In practice, the ideal candidate is someone who has tried lifestyle modification alone and hasn’t achieved sustained results, who understands these are likely long-term medications (weight regain after discontinuation is well-documented), and who has no contraindications. That last part matters.
Who Shouldn’t Take Them
These are not lifestyle drugs. The absolute contraindications are serious:
- Personal or family history of medullary thyroid carcinoma (MTC)
- Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
- Known serious hypersensitivity to any GLP-1 medication
- Type 1 diabetes — these are not insulin replacements
- History of diabetic ketoacidosis
- Pregnancy or breastfeeding — not studied, not recommended
Additional conditions require careful clinical judgment: a history of pancreatitis (GLP-1s have been associated with acute pancreatitis, though the absolute risk is low), severe gastroparesis, active gallbladder disease, and significant kidney impairment. None of these are automatic disqualifiers, but they demand an honest conversation with a prescribing physician — not a telehealth checkbox.
Natural Alternatives and Lifestyle: What Actually Moves the Needle
No food or supplement replicates what injectable GLP-1 agonists do. The pharmacological concentrations these drugs achieve — keeping GLP-1 receptors activated around the clock — are orders of magnitude beyond what diet alone can produce. Anyone claiming otherwise is selling something.
But that doesn’t mean the natural side of the equation is worthless. Several evidence-backed strategies support the same metabolic pathways, just at a milder, more physiologic scale:
- Berberine: Frequently called “nature’s Ozempic” on social media, berberine is a plant alkaloid that activates AMPK — the same metabolic pathway triggered by fasting and exercise. A 2024 meta-analysis found roughly 3–5% weight loss over 3 months at 500 mg two to three times daily, alongside improvements in insulin sensitivity and lipid profiles. It’s real but modest — roughly a tenth of what the injectables deliver.
- High-protein diets: Protein is the single most effective dietary lever for endogenous GLP-1 stimulation. Aiming for 25–35 grams per meal — from eggs, Greek yogurt, lean meat, legumes, or whey — demonstrably increases satiety signaling and reduces post-meal glucose excursions.
- Soluble fiber: Psyllium husk, oats, chia seeds, and legumes slow gastric emptying (sound familiar?) and stimulate GLP-1 release from intestinal L-cells. Taking psyllium 30 minutes before meals has a measurable effect on appetite and portion control.
- Green tea (EGCG) and curcumin: Both show modest GLP-1-boosting effects in preliminary research, though human trial data remains thin. They’re reasonable additions to a dietary pattern, not replacements for medical therapy.
- Resistance training: Preserving lean mass during weight loss is critical, and GLP-1 drugs don’t do it for you. Patients who combine these medications with structured strength training lose less muscle and have better long-term metabolic outcomes. Read our evidence-based guide on losing belly fat for strategies that pair well with — or substitute for — medication approaches.
The dietary pattern that consistently emerges in the research as most compatible with metabolic health — regardless of whether someone is on medication — is a Mediterranean-style approach: plant-forward, rich in fiber, moderate in lean protein, low in ultra-processed foods. For women navigating weight changes during menopause in particular, dietary strategy matters enormously. See our roundup of the best diets for women over 50 for age-specific evidence and practical meal frameworks.
The Oral GLP-1 Pipeline: Needles Aren’t Forever
If the biggest barrier to GLP-1 adoption is the injection — and for many patients, it is — the oral pipeline is about to change the landscape dramatically.
In December 2025, the FDA approved oral Wegovy (semaglutide 25 mg daily), making it the first oral GLP-1 therapy specifically indicated for weight loss. The catch: oral semaglutide requires an empty stomach and only a small sip of water — taken first thing in the morning, with at least 30 minutes before eating or drinking anything else. That’s a compliance hurdle many patients struggle with.
Then, in April 2026, the FDA approved Foundayo (orforglipron), Eli Lilly’s once-daily oral small-molecule GLP-1 — and this one changes the game. Unlike oral semaglutide, orforglipron can be taken at any time of day with no food or water restrictions. In the ATTAIN-1 trial, it produced roughly 11–12% weight loss at 72 weeks. That trails the injectables, but the convenience profile is a different value proposition entirely.
Further out, the pipeline gets even more interesting. Retatrutide (Eli Lilly’s triple agonist targeting GLP-1, GIP, and glucagon receptors) posted up to 28.7% weight loss in Phase 3 — approaching bariatric surgery territory — with an FDA filing expected late 2026. Aleniglipron (Structure Therapeutics) and VK2735 (Viking Therapeutics) are oral candidates in Phase 2–3 with early data suggesting weight loss in the 12–16% range. We’ve covered the full oral weight-loss drug landscape here — including timelines, efficacy data, and what it means for people who’ve been waiting for a pill.
Cost and Insurance: The Elephant in the Exam Room
Let’s talk dollars, because the clinical conversation means nothing if you can’t afford the prescription.
Without insurance, these drugs cost roughly $900 to $1,350 per month at U.S. list prices. Wegovy sits at the high end (around $1,349/month), Zepbound around $1,086, Mounjaro roughly $1,069–1,079, and Ozempic approximately $1,028. These are list prices — negotiated rates and rebates can be lower, but for the uninsured or underinsured, these numbers are real.
The manufacturer savings programs change the math for commercially insured patients. With eligible commercial insurance, copays can drop as low as $25 per month for all three brands. The catch: these programs typically don’t apply to Medicare, Medicaid, or uninsured patients.
Medicare coverage has been a moving target. Historically, Medicare was barred by statute from covering weight-loss drugs. That shifted with the Medicare GLP-1 Bridge program, launching July 1, 2026 — an 18-month pilot that covers Wegovy (injection and pill), Zepbound KwikPens, and Foundayo for eligible Part D enrollees at a flat $50 monthly copay. Eligibility requires a BMI of 35 or higher with a documented commitment to lifestyle changes. Ozempic and Mounjaro — approved for diabetes, not weight loss — are not included in this program, though they remain covered under their diabetes indications.
Medicaid coverage varies by state. As of January 2026, only 13 state Medicaid programs covered GLP-1s for obesity treatment. For diabetes or cardiovascular indications, coverage is federally required.
Compounded versions — produced by compounding pharmacies during FDA-declared shortages — have offered a lower-cost path ($99–199/month), but this option shrinks as manufacturing capacity catches up with demand and the shortage designations are resolved. Patients considering this route should understand that compounded products are not FDA-approved and carry different quality and safety standards than brand-name formulations.
The Bottom Line
If you’re comparing these three drugs purely on clinical efficacy, the hierarchy is clear: tirzepatide (Mounjaro/Zepbound) > semaglutide 2.4 mg (Wegovy) > semaglutide 1 mg (Ozempic). The SURMOUNT-5 trial closed the debate: tirzepatide produces roughly 47% greater relative weight loss than semaglutide at maximum doses.
But efficacy isn’t everything. The “best” choice depends on what your insurance covers, how you tolerate side effects, whether you have type 2 diabetes (which changes the approval pathway), and whether you have personal or family risk factors that rule out the entire class. Some people do better on semaglutide simply because they tolerate it better. Some people’s insurance covers Wegovy but not Zepbound, and in that scenario, Wegovy is the best drug because it’s the one you can actually access.
No medication in this class is a substitute for nutrition, movement, and metabolic health habits — including protein intake, resistance training, and sleep quality. The drugs are powerful tools, but they work best as part of a complete lifestyle strategy, not a replacement for one. And if you’re considering going this route, start with a conversation with a physician who knows your full medical history — not a social media post, not a telehealth ad, not a wellness influencer.




